

Itepekimab Biosimilar - Research Grade

Product Code: ICH5249

More Information

Species Reactivity: Human

Target: IL33

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Itepekimab Biosimilar - Research Grade

Antibodies against the same target: [Etokimab Biosimilar - Research Grade \(ICH5061\)](#), [Torudokimab Biosimilar - Research Grade \(ICH5280\)](#), [Tozorakimab Biosimilar - Research Grade \(ICH5938\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: O95760

Shipping Conditions: Blue ice

background: ICH5249 is an unconjugated, non-therapeutic recombinant analog of itepekimab, an anti-IL-33 human IgG4-kappa antibody, supplied strictly for research use. It reproduces the antigen-binding specificity of the originator molecule, which was raised against human interleukin-33 (IL-33, UniProt O95760), so that laboratories can study IL-33 neutralization and IL-33/ST2 pathway biology without sourcing clinical material. The recombinant format gives lot-to-lot consistency and lets it serve as a defined reference or positive control in binding, blocking, and cell-based assays alongside other anti-IL-33 or anti-alarmin reagents. It is offered at low endotoxin (research grade 1 EU/mg; ultra-low 0.5 EU/mg options) and in bulk milligram-to-gram quantities to support screening cascades,

assay standardization, and preclinical in-vitro work. As a human-target biosimilar analog it is intended for functional characterization, method development, and comparability studies, not for therapeutic, diagnostic, human, or veterinary use. It is not the clinical drug product and carries no clinical claims; all content here is guidance for ichorbio to review before publication. Interleukin-33 (IL-33, UniProt O95760) is an IL-1 family cytokine and a member of the epithelial-derived "alarmins." It is constitutively expressed in the nucleus of barrier and structural cells, notably epithelial cells of the lung, gut and skin, and endothelial cells, where full-length IL-33 is bound to chromatin. On cell damage, necrosis, or stress it is released into the extracellular space, acting as a danger signal. Extracellular IL-33 signals through its receptor ST2 (IL1RL1) together with the co-receptor IL-1RAcP, driving MyD88-dependent NF- κ B and MAPK activation. It potently activates type 2 immunity, stimulating ILC2s, Th2 cells, mast cells, basophils, eosinophils and regulatory T cells to produce IL-5 and IL-13. IL-33 bioactivity is modulated by proteolytic maturation and by oxidation, which limits its active window. It is strongly implicated in asthma, COPD and allergic and fibrotic disease.

Other names: Interleukin-1 family member 11, IL-1F11, Nuclear factor from high endothelial venules, NF-HEV, Interleukin-33, C9orf26

Specificity: Detects human IL33

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.



Delivery Time: 4 weeks